Theranexus

Biotechnology ResearchAuvergne-rhône-alpes, France11-50 Employees

THX Pharma (Theranexus) is a pharmaceutical company specializing in treatments for rare neurological diseases. Its first drug, TX01, will soon be commercialized—particularly in Europe by Exeltis, but also in the United States, Canada, and Australia—for Niemann-Pick type C disease and Gaucher disease. Its second drug, Batten-1, targets the juvenile form of Batten disease and could become the first approved therapy for this condition. THX Pharma also has an innovative antisense oligonucleotide platform, co-developed with leading research laboratories, dedicated to rare neurological diseases.
THX Pharma, a trade name of Theranexus, is listed on Euronext Growth Paris (FR0013286259 – ALTHX).

Sign up for free to view info

Email Format Employee directory